武田制药 TAK 深 沪
等待开盘 02-10 09:30:00 美东时间
17.73
-0.160
-0.89%
华盛通- 最 高17.79
- 今 开17.71
- 成交量 232.04万股
- 最 低 17.58
- 昨 收 17.89
- 总市值 560.12亿
- 52周最高 17.985
- 市盈率 静 80.41
- 换手率 0.07%
- 52周最低 12.99
- 委 比 38.59%
- 总股本 31.59亿
- 历史最高 17.985
- 量 比 0.69
- 振 幅 1.17%
- 历史最低 8.7904
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Takeda, Iambic ink AI drug discovery deal worth more than $1.7B
U.S. biotech Iambic on Monday announced a multi-year agreement that could potentially be worth more than $1.7B with Takeda (TAK) to develop small molecule drugs leveraging its AI-led drug discovery te...
02-09 23:34
武田制药以17亿美元收购Iambic 加码人工智能药物研发布局
私人控股企业Iambic于本周一宣布，已与日本武田制药达成价值超17亿美元的多年期合作，双方将借助人工智能技术，助力研发针对癌症和胃肠道疾病的小分子药物。...
02-09 21:26
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio
Alvotech (ALVO) shares spiked ~3% in the premarket on Thursday after the Luxembourg-based biotech succeeded in a study designed to evaluate AVT80, its proposed biosimilar to Entyvio, a bowel disease t...
02-05 21:15
Takeda Updates FY2025 Outlook, Revises Core Revenue To Low-Single-Digit Decline While Maintaining Low-Single-Digit Declines In Core Operating Profit And Core EPS
FY2025 OutlookUpdating Full Year Management Guidance for Revenue and ForecastsTakeda has updated its full year Management Guidance for Revenue primarily due to VYVANSE and raised full year forecasts to reflect cost
01-29 15:05
Takeda Pharmaceutical Q3 Adj. EPS $0.47 Misses $0.55 Estimate, Sales $7.600B Miss $8.530B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.55 by 13.64 percent. This is a 7.95 percent increase over earnings of $0.44 per share from
01-29 14:58
日经指数上涨0.6% 受金融股和电子股带动
日本日经指数上涨0.6%，报53，698.24点，金融股和电子股的上涨帮助抵消了零售股和科技股的下跌影响。日本邮政银行上涨3.3%，铠侠上涨6.0%，而永旺...
01-29 08:26
Takeda Pharmaceutical Q3 Earnings Preview
Takeda Pharmaceutical (TAK) is scheduled to announce Q3 earnings results on Thursday, January 29th, before market open. Analysts on average of GAAP EPS of JPY 43.14 on revenue of JPY 1.193T. More on T...
01-29 00:20
跨国药企扫货中国创新药 谁是首席买家
经济观察报 记者 张英 2026年摩根大通医疗健康大会（JPM）已结束一周，多家跨国公司在会上明确表达对中国资产的兴趣。 多位受访者对经济观察报表示，其所在药企...
01-25 10:22
